Psoriatic Disease

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.

Interleukin-17 and IL-23 inhibitors do not increase the risk for tuberculosis reactivation among patients with psoriatic disease who have a latent tuberculosis infection, according to a retrospective study.

DESTIN, Fla. — The course of difficult-to-treat psoriatic arthritis can be significantly impacted by a host of factors beyond choice of therapy, according to data presented at the Congress of Clinical Rheumatology East annual meeting.

Patients with psoriatic arthritis who receive deucravacitinib report significant improvements in mental health, pain, fatigue and other outcomes vs. placebo, according to data published in Arthritis Care & Research.

Rheumatologists should turn to biologics as usual treatment in patients with psoriatic arthritis who demonstrate an inadequate response to methotrexate, according to new EULAR recommendations.

ARCA biopharma and Oruka Therapeutics have entered into a definitive merger agreement and will now operate under Oruka Therapeutics, ARCA announced in a press release.

Patients with psoriatic arthritis in Canada face “substantial burden and unmet need” for improved treatments, as nearly 75% fail to achieve minimal disease activity within 6 months of starting advanced therapy, according to data.

Patients with active psoriatic arthritis who receive guselkumab demonstrate reduced work impairment, improved overall health and “substantial cost savings” through 2 years, according to data published in Rheumatology and Therapy.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.

The FDA has approved Simlandi as the third interchangeable biosimilar to Humira following a rejection in April 2023 stemming from issues at the developer’s manufacturing facility.